EMBO Member
University of Oxford | United Kingdom
EMBO 2006
Previous research focusing on rate limiting steps in the pathogenesis of rheumatoid arthritis uncovered TNF-alpha as the key mediator and led to development of anti-TNF therapy, currently the best-selling pharmaceuticals. I aim to get closer to a cure by defining other rate limiting steps. Discovering TNF as a target was based on using human disease tissue, and working with colleagues analysing human disease tissue we detected therapeutic targets in atherosclerosis, fractures and fibrosis.
Keywords: Immunotherapy / anti-TNF / rheumatoid arthritis / autoimmune diseases / cytokines
Subject area(s): Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology | Immunology